COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs.
Warner
Timothy D
TD
The William Harvey Research Institute, Barts and the London, Queen Mary's School of Medicine and Dentistry, London, UK. t.d.warner@qmul.ac.uk
Mitchell
Jane A
JA
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005767:Gastrointestinal Diseases / Q000139:chemically induced*; D006801:Humans; D009203:Myocardial Infarction / Q000139:chemically induced; D012307:Risk Factors; D013927:Thrombosis / Q000139:chemically induced*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors